While the top- and bottom-line numbers for Tenet (THC) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
On Wednesday, Tenet Healthcare Corporation THC reported first-quarter sales of $5.37 billion, up around 7% year over year, beating the consensus of $5.15 billion.
Tenet Healthcare (THC) came out with quarterly earnings of $2.31 per share, beating the Zacks Consensus Estimate of $1.89 per share. This compares to earnings of $1.44 per share a year ago.
Tenet (THC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Tenet Healthcare (THC) closed the most recent trading day at $133.27, moving +1.15% from the previous trading session.
Tenet Healthcare's (THC) second-quarter earnings are likely to have benefited from higher admissions, average length of stay and patient days.
In the latest trading session, Tenet Healthcare (THC) closed at $131.75, marking a -1.26% move from the previous day.
Tenet (THC) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Tenet (THC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tenet Healthcare (THC) closed at $134.39 in the latest trading session, marking a +0.49% move from the prior day.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.